Get the Stockscreener App
38.71
1.50%
-0.59
After Hours:
38.71
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $195,350.00 in Stock - MarketBeat
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - The Manila Times
Crinetics Q4 Earnings Date Confirmed: Key Financial Updates Expected Feb 27 - StockTitan
Crinetics Pharmaceuticals Inc (CRNX)’s Market Momentum: Closing Strong at 39.30, Down -2.72 - The Dwinnex
An analyst sees good growth prospects for Crinetics Pharmaceuticals Inc (CRNX) - SETE News
Calamos Advisors LLC Trims Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Wolfe Research Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers - Insider Monkey
Keeping an Eye on Crinetics Pharmaceuticals Inc (CRNX) After Insider Trading Activity - Knox Daily
Wolfe Research Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Peer Perform Recommendation - MSN
KBC Group NV Grows Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Wolfe starts Crinetics at Peer Perform, believes hedge funds turning bearish - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Wolfe Research - MarketBeat
Wolfe Research Initiates Coverage on Crinetics Pharmaceuticals With Peer Perform Rating - Marketscreener.com
Jennison Associates LLC Has $138.48 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Crinetics Pharmace - GuruFocus.com
What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)? - MSN
(CRNX) On The My Stocks Page - Stock Traders Daily
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of “Buy” by Brokerages - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by SG Americas Securities LLC - MarketBeat
Analysts Set Expectations for CRNX FY2025 Earnings - Defense World
Crinetics upgraded to buy by Jefferies, atumelnant potential cited - MSN
Jefferies turns bullish on Crinetics stock, citing overlooked CAH market potential - MSN
Jefferies Financial Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to "Buy" - MarketBeat
Brokers Offer Predictions for CRNX FY2025 Earnings - MarketBeat
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Large Increase in Short Interest - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Up 3.12%: This Is What Analysts Are Now Forecasting - Stocks Register
Crinetics falls after mid-stage trial data adrenal disorder therapy - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Receives “Buy” Rating from HC Wainwright - Defense World
Crinetics Pharmaceuticals' (CRNX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by JPMorgan Chase & Co. - Defense World
CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Grants Stock Options to 17 New Employees in Key Expansion Move - StockTitan
Crinetics reports positive results in CAH treatment study By Investing.com - Investing.com Australia
Crinetics stock falls after CAH therapy data (CRNX:NASDAQ) - Seeking Alpha
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2 - TipRanks
Crinetics reports positive results in CAH treatment study - Investing.com India
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):